Traders Sell Shares of Eli Lilly And Co (LLY) on Strength (LLY)
Traders sold shares of Eli Lilly And Co (NYSE:LLY) on strength during trading on Friday. $37.73 million flowed into the stock on the tick-up and $76.53 million flowed out of the stock on the tick-down, for a money net flow of $38.80 million out of the stock. Of all equities tracked, Eli Lilly And Co had the 0th highest net out-flow for the day. Eli Lilly And Co traded up $0.06 for the day and closed at $102.25
A number of equities research analysts recently issued reports on LLY shares. HC Wainwright reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, April 18th. Credit Suisse Group set a $80.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Sunday, April 22nd. BMO Capital Markets restated a “hold” rating and set a $79.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, April 24th. ValuEngine downgraded Eli Lilly And Co from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, Barclays set a $98.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, May 22nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co has an average rating of “Hold” and a consensus price target of $100.13.
The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The stock has a market cap of $109.75 billion, a price-to-earnings ratio of 23.89, a PEG ratio of 1.70 and a beta of 0.27.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Stockholders of record on Wednesday, August 15th will be issued a $0.5625 dividend. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.20%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
In other news, SVP Christi Shaw sold 8,426 shares of Eli Lilly And Co stock in a transaction dated Tuesday, May 29th. The stock was sold at an average price of $82.10, for a total value of $691,774.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $83.85, for a total value of $15,093,000.00. Following the completion of the transaction, the insider now owns 122,575,804 shares in the company, valued at approximately $10,277,981,165.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,575,728 shares of company stock worth $144,624,164. Company insiders own 0.11% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its stake in shares of Eli Lilly And Co by 14.1% in the first quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after purchasing an additional 4,022,251 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Eli Lilly And Co by 103.8% in the first quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock worth $362,806,000 after purchasing an additional 2,388,548 shares during the last quarter. BlackRock Inc. grew its stake in shares of Eli Lilly And Co by 3.0% in the first quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock worth $5,089,436,000 after purchasing an additional 1,926,334 shares during the last quarter. Investec Asset Management LTD grew its stake in shares of Eli Lilly And Co by 49.6% in the second quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock worth $215,738,000 after purchasing an additional 838,271 shares during the last quarter. Finally, LSV Asset Management bought a new stake in shares of Eli Lilly And Co in the first quarter worth about $60,658,000. Hedge funds and other institutional investors own 76.62% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Outstanding Shares
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.